Levosimendan
- Generic Name
- Levosimendan
- Drug Type
- Small Molecule
- Chemical Formula
- C14H12N6O
- CAS Number
- 141505-33-1
- Unique Ingredient Identifier
- C6T4514L4E
Overview
Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
Background
Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
Indication
For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.
Associated Conditions
- Acute Decompensated Heart Failure (ADHF)
- Acute Decompensation of Chronic Heart Failure
- Acute Heart Failure (AHF)
- Chronic Heart Failure (CHF)
- Acute post-surgical heart failure
- Acute, chronic Decompensated Heart Failure
- Heart failure post-myocardial infarction
- Severe Decompensated Chronic Heart Failure
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.